Gensia: Never say die

When it finally brings its GenESA System to the U.S. market in the third quarter, Gensia Sicor still will not be selling the coronary artery disease diagnostic system for the full indication the company had sought. But having waited and worked as long as it has - GNSA has been through two rounds

Read the full 536 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE